MAP
INDV icon

Madison Avenue Partners’s Indivior Pharmaceuticals INDV Stock Holding History

Madison Avenue Partners’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$118M Sell
2,874,368
-1,440,794
-33% -$52.3M 5.08% 9
2026
Q1 		$132M Sell
4,315,162
-1,965,340
-31% -$64.9M 5.72% 8
2025
Q4 		$225M Sell
6,280,502
-183,083
-3% -$5.59M 9.68% 4
2025
Q3 		$156M Sell
6,463,585
-1,458,593
-18% -$30.5M 9.3% 4
2025
Q2 		$117M Buy
7,922,178
+130,089
+2% +$1.52M 7.8% 5
2025
Q1 		$74.3M Buy
7,792,089
+4,118,663
+112% +$43.3M 6.3% 6
2024
Q4 		$45.7M Sell
3,673,426
-287,346
-7% -$2.96M 4.84% 9
2024
Q3 		$38.6M Buy
3,960,772
+3,737,340
+1,673% +$43.8M 3.58% 9
2024
Q2 		$3.6M Buy
223,432
+60,537
+37% +$1.09M 0.46% 16
2024
Q1 		$3.49M Buy
162,895
+90,640
+125% +$1.7M 0.56% 17
2023
Q4 		$1.1M Buy
72,255
+33,168
+85% +$589K 0.16% 17
2023
Q3 		$902K Buy
39,087
+27,887
+249% +$636K 0.13% 18
2023
Q2 		$267K Buy
+11,200
New +$257K 0.06% 19

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Madison Avenue Partners's INDV Position: Q2 2026 in Review

Madison Avenue Partners reduced its Indivior Pharmaceuticals (INDV) stake by 33% in Q2 2026, selling an estimated $52.3M and leaving 2,874,368 shares worth $118M. The position accounts for 5.08% of the portfolio, ranked #9.

Madison Avenue Partners first reported a position in INDV in Q2 2023 and has held it in 13 quarters since. The position peaked at $225M in Q4 2025. 338 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Madison Avenue Partners held 2,874,368 shares of Indivior Pharmaceuticals worth $118M as of Q2 2026.
  • Madison Avenue Partners sold 1,440,794 Indivior Pharmaceuticals shares in Q2 2026, an estimated $52.3M.
  • Indivior Pharmaceuticals made up 5.08% of Madison Avenue Partners's portfolio in Q2 2026, its #9 holding.
  • Madison Avenue Partners first reported a position in Indivior Pharmaceuticals in Q2 2023 and has held it in 13 quarters since.
  • Madison Avenue Partners's Indivior Pharmaceuticals position peaked at $225M in Q4 2025.
  • 338 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Madison Avenue Partners's 13F filing for Q2 2026, filed 14 Aug 2026.